Ginkgo Bioworks DNA Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number at other companies

ClearPoint NeuroCLPT

——

Twist Bioscience CorporationTWST

——

Other financials

Income statement

See full

Revenue$19.5M-49.1%

Gross profit$16.4M-52.0%

Operating income-$71.4M+11.9%

Net income-$82.6M+9.2%

EPS (diluted)-$1.42+27.6%

Balance sheet

See full

Cash & equivalents$188.7M-46.9%

Total debt$410.7M-5.5%

Total equity$443.2M-31.6%

Total assets$1.0B-20.1%

Cash flow

See full

Operating cash flow-$46.7M+9.4%

CapEx$1.9M-74.6%

Free cash flow-$48.6M+17.8%

Valuation

See full

Market cap$625.16M+24.6%

Enterprise value$847.19M+45.9%

P/S4.4×+2.2×

Profitability

See full

Operating margin-210.7%+7.6pp

Net margin-215.4%+8.3pp

FCF margin-119%-21.2pp

Returns & leverage

See full

Return on equity-55.8%-1.8pp

Debt / equity0.9×+0.3×

Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's share based compensation arrangement by share based payment award options exercisable number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ginkgo Bioworks's share based compensation arrangement by share based payment award options exercisable number?: Ginkgo Bioworks (DNA) reported share based compensation arrangement by share based payment award options exercisable number of $136.01K in Q1 2026.
How has Ginkgo Bioworks's share based compensation arrangement by share based payment award options exercisable number changed year-over-year?: Ginkgo Bioworks's share based compensation arrangement by share based payment award options exercisable number increased by 397.5% year-over-year, from $27.34K to $136.01K.